Claude Bertrand to step down as Executive Vice President, R&D, Chief Scientific Officer of Ipsen
Alexandre Lebeaut, MD will lead the R&D division in the interim.
Paris (France), 12 December 2016 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that Claude Bertrand, Executive Vice President, R&D, Chief Scientific Officer, will depart Ipsen on January 2nd, 2017, to join another company. Pending Claude Bertrand’s replacement, Alexandre Lebeaut, MD, will lead the R&D division in the interim. Dr. Lebeaut, Senior Vice President, Global Drug Development joined Ipsen in 2012, bringing a long and solid medical and managerial experience after having spent more than 20 years in large pharmaceutical and biotechnology companies, with extensive international experience in Italy, France, and mostly North America.
David Meek, CEO of Ipsen, said, “On behalf of the company, I would like to thank Dr. Bertrand for his significant contribution to leading the R&D organization during the past seven years. We wish him well as he moves on to pursue a new opportunity. We are fortunate to have an experienced and successful R&D leader like Dr. Lebeaut to step up and lead the R&D team.”